PHIO Stock — Phio Pharmaceuticals Corp.: Cash, EV, Pipeline

Share price

$1.03

Market cap

$12.0M

Cash

$13.0M

Enterprise value

-$1.0M

Balance sheet

Cash	$13.0M
Debt	$0.0M
Net cash	$13.0M
Enterprise value	-$1.0M
Basic shares	11.6M shares
Fully diluted shares	25.8M shares
Fully diluted market cap	$26.6M
Cash per share	$1.12

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading PHIO daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 11 - Mar 25	DP CD8 TIL	Phase 1	HNSCC; Melanoma; Gynecologic Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PH-762

Phase 1 · Active Modality: siRNA

Target PD-1

Indications

Cutaneous squamous cell carcinoma (cSCC) (Phase 1)

Catalysts

— third quarter 2026

Status note INTASYL self-delivering siRNA compound. Evaluated via intratumoral administration in a U.S. multi-center Phase 1b dose-escalating trial in cSCC.

PH-894

Preclinical · Active Modality: siRNA

Target BRD4

Indications

Cancer (Preclinical)

Status note INTASYL compound targeting BRD4. Preclinical; the Company is weighing whether/when to fund additional pipeline programs including PH-894.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PH-762
Lead indication	Squamous Cell Carcinoma of the Skin
Lead phase	Phase 1
Active trials	1
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06014086	Phase 1	Active, not recruiting	Sponsor	Phio Pharmaceuticals Inc.	—	Squamous Cell Carcinoma of the Skin; Malignant Melanoma of Skin; Merkel Cell Carcinoma of Skin	—
NCT05902520	Phase 1	Active, not recruiting	Collaborator	AgonOx, Inc.	—	HNSCC; Melanoma; Gynecologic Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Phio Pharmaceuticals Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

PHIO — Phio Pharmaceuticals Corp.